These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12954135)

  • 21. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of antithyroid medication on the effective half-life and uptake of 131-iodine following radioiodine therapy].
    Moka D; Voth E; Schicha H
    Nuklearmedizin; 1997 Apr; 36(3):87-92. PubMed ID: 9162907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
    Bakker SC; Zanin DE; Zweers EJ
    Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External dose rates in radioiodine treatment of benign goitre: estimation versus direct measurement.
    Jørgensen HB; Høilund-Carlsen PF; Nielsen VE
    Scand J Clin Lab Invest; 2006; 66(6):509-16. PubMed ID: 17000558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.
    Ruchała M; Sowiński J; Dolata M; Junik R; Gembicki M; Skiba A
    Nucl Med Rev Cent East Eur; 2005; 8(1):28-32. PubMed ID: 15977144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
    Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The value of a tracer dose in predicting the kinetics of therapeutic doses of 131I in thyrotoxicosis.
    O'Connor MK; Cullen MJ; Malone JF
    Br J Radiol; 1979 Sep; 52(621):719-26. PubMed ID: 476386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Excess radiation absorbed doses from non-optimised radioiodine treatment of hyperthyroidism.
    Jönsson H; Mattsson S
    Radiat Prot Dosimetry; 2004; 108(2):107-14. PubMed ID: 14978290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective randomized comparison of intravenous versus subcutaneous administration of radioiodine for treatment of hyperthyroidism in cats.
    Théon AP; Van Vechten MK; Feldman E
    Am J Vet Res; 1994 Dec; 55(12):1734-8. PubMed ID: 7887519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iodine prophylaxis intensification. Influence on radioiodine uptake and activity of 131I used in the treatment of hyperthyroid patients with Graves' disease.
    Baczyk M; Junik R; Ziemnicka K; Sowiński J
    Nuklearmedizin; 2005; 44(5):197-9. PubMed ID: 16395495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome.
    Walter MA; Christ-Crain M; Eckard B; Schindler C; Nitzsche EU; Müller-Brand J; Müller B
    Eur J Clin Invest; 2004 May; 34(5):365-70. PubMed ID: 15147334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
    Urbannek V; Voth E; Moka D; Schicha H
    Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Reduction of thyroid volume following radioiodine therapy for functional autonomy].
    Luster M; Jacob M; Thelen MH; Michalowski U; Deutsch U; Reiners C
    Nuklearmedizin; 1995 Apr; 34(2):57-60. PubMed ID: 7761274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.
    Liu B; Tian R; Peng W; He Y; Huang R; Kuang A
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2934-41. PubMed ID: 26046966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimization of (131)I doses for the treatment of hyperthyroidism.
    Araujo F; Rebelo AM; Pereira AC; Moura MB; Lucena EA; Dantas AL; Dantas BM; Corbo R
    Cell Mol Biol (Noisy-le-grand); 2009 Nov; 55(3):1-6. PubMed ID: 20003804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiation dosimetry for the adult female and fetus from iodine-131 administration in hyperthyroidism.
    Stabin MG; Watson EE; Marcus CS; Salk RD
    J Nucl Med; 1991 May; 32(5):808-13. PubMed ID: 2022987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of hyperthyroidism with radioiodine targeted activity: A comparison between two dosimetric methods.
    Amato E; Campennì A; Leotta S; Ruggeri RM; Baldari S
    Phys Med; 2016 Jun; 32(6):847-53. PubMed ID: 27245300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.